Endorphins — research review 1

...and this is where endorphins, our body's natural pain relievers, enter the conversation. We know they're released by things like exercise, but what about their long-term impact on aging and mortality when used as pain treatment?

It’s a complex picture. While endorphins are crucial for acute pain relief, long-term opioid use, which acts on the same pathways, raises questions. A study in Public Health (2024) found that chronic opioid use was associated with a 37% higher risk of all-cause mortality compared to short-term use.

That’s a significant statistic. And the risks seem to compound, right? I recall seeing something about combinations with other medications.

Exactly. Research in Frontiers in Pharmacology (2022) highlighted that opioid-gabapentinoid combination therapy was associated with a 2.76 times increased risk of CNS depression and mortality. These are serious concerns, especially for older adults.

So, on one hand, we have these potential long-term harms with opioid pathways. But what about the harm of not treating chronic pain? How does that factor into biological aging?

That’s the critical balance. Untreated chronic pain itself can accelerate biological aging. For example, GeroScience (2025) found painful diabetic neuropathy was linked to accelerated epigenetic aging and telomere shortening compared to painless neuropathy.

So, it's not simply a matter of avoiding medication. It’s about careful, supervised management. What’s still unknown, though, about endorphins and biological aging specifically?

We still need more direct evidence on how endogenous endorphin modulation, separate from exogenous opioids, impacts the epigenetic clock and all-cause mortality over decades. The link is mostly inferred from opioid research and the impact of chronic pain itself. The precise mechanisms and optimal strategies for long-term pain management to minimize overall mortality and aging effects remain areas of active research.